AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28861843 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory discrimination training
Number of subjects: 39
Study 28861843 — intervention group
Group type: COMPARATOR
Intervention: Simple object manipulation (Control)
Number of subjects: 39
Study 27418251 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin treatment
Number of subjects: 5
Study 27418251 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 5
Study 24034685 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements for alternative nicotine products
Number of subjects: 1062
Study 24034685 — intervention group
Group type: COMPARATOR
Intervention: Advertisements for soft drinks
Number of subjects: 1062
Study 24034685 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant advertisements
Number of subjects: 1062
Study 22486134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg daily for 6 months
Number of subjects: 50
Study 22486134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21138627 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (without anti-viral therapy)
Number of subjects: 177
Study 21138627 — intervention group
Group type: COMPARATOR
Intervention: Control group (received lamivudine therapy)
Number of subjects: 177
Study 21138627 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral group (HBeAg negative)
Number of subjects: 177
Study 21138627 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral group (HBeAg positive)
Number of subjects: 177
Study 21138627 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral group
Number of subjects: 177
Study 18702961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus N-acetylcysteine (NAC)
Number of subjects: 502
Study 18702961 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline plus N-acetylcysteine (NAC)
Number of subjects: 502
Study 18702961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus NAC
Number of subjects: 502
Study 18702961 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline plus NAC
Number of subjects: 502
Study 15995439 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-augmented hypotensive epidural anesthesia without use of a tourniquet (Group A)
Number of subjects: 100
Study 15995439 — intervention group
Group type: COMPARATOR
Intervention: Normotensive epidural anesthesia with use of a tourniquet (Group B)
Number of subjects: 100
Study 15995439 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-augmented hypotensive epidural anesthesia (Group A)
Number of subjects: 100
Study 12859561 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 12
Study 12859561 — intervention group
Group type: COMPARATOR
Intervention: Diluent (placebo)
Number of subjects: 12
Study 10473963 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol (ROL)
Number of subjects: 361
Study 10473963 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinaldehyde (RAL)
Number of subjects: 361
Study 10473963 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoic Acid (RA)
Number of subjects: 361
Study 8933962 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hr of bedrest after angiography using five or six French catheters
Number of subjects: 205
Study 8933962 — intervention group
Group type: COMPARATOR
Intervention: 4 hr of bedrest after angiography using five or six French catheters
Number of subjects: 205
Study 8933962 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hr of bedrest after angiography using seven French catheters
Number of subjects: 205
Study 8933962 — intervention group
Group type: COMPARATOR
Intervention: 4 hr of bedrest after angiography using seven French catheters
Number of subjects: 205
Study 1932377 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF) treatment
Number of subjects: 0
Study 1932377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6416184 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful alone
Number of subjects: 0
Study 6416184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MMC and Futraful
Number of subjects: 0
Study 6416184 — intervention group
Group type: COMPARATOR
Intervention: MMC alone
Number of subjects: 0
Study 29895522 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat antenatal betamethasone
Number of subjects: 266
Study 29895522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 29734536 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP and RS blocks (Group B)
Number of subjects: 36
Study 25102853 — intervention group
Group type: EXPERIMENTAL
Intervention: VMP (bortezomib plus melphalan and prednisone)
Number of subjects: 260
Study 25102853 — intervention group
Group type: COMPARATOR
Intervention: VTP (bortezomib plus thalidomide and prednisone)
Number of subjects: 260
Study 25102853 — intervention group
Group type: EXPERIMENTAL
Intervention: VMP
Number of subjects: 260
Study 25102853 — intervention group
Group type: COMPARATOR
Intervention: VTP
Number of subjects: 260
Study 22329593 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 80
Study 22329593 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 80
Study 20597558 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate injection plus thumb spica cast
Number of subjects: 73
Study 20597558 — intervention group
Group type: COMPARATOR
Intervention: Casting alone
Number of subjects: 73
Study 18728131 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular technique (group A)
Number of subjects: 45
Study 18728131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangential technique (group B)
Number of subjects: 45
Study 16191750 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (20 microg/kg) via nasal spray
Number of subjects: 17
Study 16191750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 microg/kg) via nasal spray
Number of subjects: 17
Study 12165576 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI381 10 mg
Number of subjects: 584
Study 12165576 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI381 20 mg
Number of subjects: 584
Study 12165576 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI381 30 mg
Number of subjects: 584
Study 12165576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study 10100391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical-semantic information retention
Number of subjects: 1
Study 10100391 — intervention group
Group type: EXPERIMENTAL
Intervention: Other types of information (pictures, shapes, propositional information)
Number of subjects: 1
Study 7776160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasulcular laser Doppler readings (LDR) with stabilizing stent
Number of subjects: 9
Study 7776160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasulcular laser Doppler readings (LDR) without stabilizing stent
Number of subjects: 9
Study 7776160 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic with vasoconstrictor
Number of subjects: 9
Study 7776160 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent stabilized LDR
Number of subjects: 9
Study 7776160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand held LDR
Number of subjects: 9
Study 2321781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal/iliohypogastric (IG/IH) nerve block with 0.25 ml/kg of 0.25% bupivacaine
Number of subjects: 60
Study 2321781 — intervention group
Group type: COMPARATOR
Intervention: Instillation nerve block with up to 0.5 ml/kg of 0.25% bupivacaine
Number of subjects: 60
Study 91434 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-platinum, vinblastine, and bleomycin combination chemotherapy
Number of subjects: 126
Study 30738344 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention instructions
Number of subjects: 20
Study 30738344 — intervention group
Group type: COMPARATOR
Intervention: Internal focus of attention instructions
Number of subjects: 20
Study 28052291 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing Lactobacillus gasseri OLL2716 (LG), 112 ml twice daily for 6 weeks
Number of subjects: 64
Study 28052291 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt, 112 ml twice daily for 6 weeks
Number of subjects: 64
Study 25886517 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based information tool and nurse-delivered telephone support
Number of subjects: 0
Study 25886517 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23651614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led indicated stepped-care program for depressive symptoms
Number of subjects: 236
Study 23651614 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 236
Study 21593577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (systemic corticosteroid for 2 weeks, inhaled corticosteroid for 16 weeks, bronchodilator(s))
Number of subjects: 142
Study 21593577 — intervention group
Group type: COMPARATOR
Intervention: Control group (current asthma treatment guidelines for 18 weeks)
Number of subjects: 142
Study 21348985 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17565246 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (doses more than 60 Gy) in post menopausal cases
Number of subjects: 941
Study 17565246 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks short course irradiation (Canadian protocol) or accelerated partial breast irradiation
Number of subjects: 941
Study 17565246 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast irradiation with concurrent chemotherapy
Number of subjects: 941
Study 17565246 — intervention group
Group type: EXPERIMENTAL
Intervention: Post mastectomy regional irradiation
Number of subjects: 941
Study 17565246 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy first before irradiation
Number of subjects: 941
Study 14748938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein, beta-carotene, or lycopene (natural isolate capsules, 15 mg/d, 4 weeks)
Number of subjects: 3
Study 14748938 — intervention group
Group type: COMPARATOR
Intervention: Lycopene or lutein (>2.00 micromol/l)
Number of subjects: 3
Study 14748938 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoids (0.50 to 1.00 micromol/l)
Number of subjects: 3
Study 14748938 — intervention group
Group type: COMPARATOR
Intervention: Control cells (no carotenoid supplementation)
Number of subjects: 3
Study 14748938 — intervention group
Group type: COMPARATOR
Intervention: Control PBL
Number of subjects: 3
Study 14748938 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL DNA resistance to oxidative damage ex vivo
Number of subjects: 3
Study 11240091 — intervention group
Group type: EXPERIMENTAL
Intervention: Single global assessment of treatment efficacy (5-point scale)
Number of subjects: 150
Study 11240091 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600/650 mg
Number of subjects: 150
Study 11240091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 150
Study 11240091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11180023 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 12.5 mg
Number of subjects: 27
Study 11180023 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 50 mg
Number of subjects: 27
Study 11180023 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 25 mg
Number of subjects: 27
Study 11180023 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 12.5 mg, 25 mg, 50 mg
Number of subjects: 27
Study 11180023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8742572 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/daily)
Number of subjects: 18
Study 8742572 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg/daily)
Number of subjects: 18
Study 1449887 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine diatrizoate
Number of subjects: 180
Study 1449887 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 180
Study 1449887 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 180
Study 6398026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone acetate 0.1%
Number of subjects: 0
Study 31427334 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose lowering drugs (OGLDs) starting with metformin and supplemented as needed with glibenclamide.
Number of subjects: 0
Study 31427334 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy.
Number of subjects: 0
Study 30019747 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 100
Study 30019747 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 100
Study 27393274 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization with TANDEM™ loaded with 150 mg of doxorubicin
Number of subjects: 71
Study 27393274 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization with TANDEM™ loaded with 100 mg of doxorubicin
Number of subjects: 71
Study 27393274 — intervention group
Group type: COMPARATOR
Intervention: High loading group (150 mg doxorubicin)
Number of subjects: 71
Study 24332254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort (n=65)
Number of subjects: 98
Study 24332254 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and SOC)
Number of subjects: 98
Study 22976568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-ligamental anaesthesia with 4% articaine with epinephrine
Number of subjects: 36
Study 22976568 — intervention group
Group type: COMPARATOR
Intervention: Negative aspiration of blood after ILA
Number of subjects: 36
Study 21319602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) therapy
Number of subjects: 0
Study 21319602 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) therapy
Number of subjects: 0
Study 21319602 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18379478 — intervention group
Group type: EXPERIMENTAL
Intervention: Afobazole (30 to 60 mg daily, mean 50 mg) for 6 weeks
Number of subjects: 32
Study 16081755 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom made mouthguard (MG)
Number of subjects: 301
Study 16081755 — intervention group
Group type: COMPARATOR
Intervention: Control (usual mouthguard behaviours) (C)
Number of subjects: 301
Study 11851576 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705
Study 11851576 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d
Number of subjects: 7705
Study 11851576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 11851576 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (both doses) in subset with increased cardiovascular risk
Number of subjects: 7705
Study 10209802 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol-noretisteron acetate treatment
Number of subjects: 48
Study 10209802 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 7797785 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms of inhaled triamcinolone once daily at 3:00 PM (QD group)
Number of subjects: 0
Study 7797785 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms of inhaled triamcinolone four times a day (QID group)
Number of subjects: 0
Study 2187604 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice ORS
Number of subjects: 2000
Study 2187604 — intervention group
Group type: COMPARATOR
Intervention: Glucose ORS
Number of subjects: 2000
Study 2187604 — intervention group
Group type: COMPARATOR
Intervention: No ORS (comparison group)
Number of subjects: 2000
Study 2187604 — intervention group
Group type: EXPERIMENTAL
Intervention: Staple-based ORS
Number of subjects: 2000
Study 30539694 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 30539694 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 28456619 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-controlled weeks (WCWs)
Number of subjects: 620
Study 26409223 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 26409223 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 23131574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprotein calorie (NPC) supplement (200-kcal daily)
Number of subjects: 109
Study 23131574 — intervention group
Group type: COMPARATOR
Intervention: Dietary counseling only (control group)
Number of subjects: 109
Study 21439167 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 51
Study 21439167 — intervention group
Group type: EXPERIMENTAL
Intervention: Supralingual immunotherapy
Number of subjects: 51
Study 21439167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SLIT and supralingual immunotherapy
Number of subjects: 51
Study 20032907 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (mCIT)
Number of subjects: 10
Study 20032907 — intervention group
Group type: COMPARATOR
Intervention: conventional physiotherapy
Number of subjects: 10
Study 16478570 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg daily for the first week, then 10 mg for 11 weeks)
Number of subjects: 20
Study 16478570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15054369 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric tissue reduction (RFVTR)
Number of subjects: 32
Study 15054369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11327520 — intervention group
Group type: EXPERIMENTAL
Intervention: homeopathically prepared mercury 12C
Number of subjects: 104
Study 11327520 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study 9159420 — intervention group
Group type: COMPARATOR
Intervention: CPA 2 mg with 35 microg of ethinylestradiol for 21 days each month (Diane group)
Number of subjects: 60
Study 9159420 — intervention group
Group type: COMPARATOR
Intervention: CPA 50 mg, days 5‐15, and ethinylestradiol 50 microg, days 5‐25, each month (CPA group)
Number of subjects: 60
Study 9159420 — intervention group
Group type: EXPERIMENTAL
Intervention: Decapeptyl 3.75 mg i.m. every 28 days with conjugated oestrogen 0.625 mg, days 1‐21, and medroxyprogesterone acetate 10 mg, days 12‐21 (GnRHa group)
Number of subjects: 60
Study 8187240 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-apheresis
Number of subjects: 54
Study 8187240 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-apheresis combined with Pravastatin and Niceritrol
Number of subjects: 54
Study 8187240 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-apheresis combined with lipid-lowering drugs
Number of subjects: 54
Study 3285254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid
Number of subjects: 0
Study 3285254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31942927 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-type fructans (ITFs) treatment
Number of subjects: 21
Study 31942927 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) treatment
Number of subjects: 21
Study 31051259 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3− supplementation with NO3−‐rich beetroot juice
Number of subjects: 11
Study 27856385 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 64
Study 27856385 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 64
Study 25263735 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placement (Ea)
Number of subjects: 44
Study 25263735 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement (De)
Number of subjects: 44
Study 23352054 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative transfusion
Number of subjects: 70
Study 23352054 — intervention group
Group type: COMPARATOR
Intervention: No preoperative transfusion
Number of subjects: 70
Study 21856267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg, BID), amoxicillin (1000 mg, BID), clarithromycin (500 mg, BID) for 14 days, plus vitamin C (500 mg, BID) and vitamin E (200 IU, BID) for 30 days (Group A)
Number of subjects: 120
Study 21856267 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg, BID), amoxicillin (1000 mg, BID), clarithromycin (500 mg, BID) for 14 days (Group B)
Number of subjects: 120
Study 17631400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 395
Study 17631400 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 150 mg/day
Number of subjects: 395
Study 17631400 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 300 mg/day
Number of subjects: 395
Study 17631400 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 150, 300, and 600 mg/day
Number of subjects: 395
Study 16543744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) diamorphine spray
Number of subjects: 4
Study 16543744 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) diamorphine
Number of subjects: 4
Study 14643039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 55
Study 14643039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 55
Study 14643039 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg
Number of subjects: 55
Study 14643039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11054329 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 245
Study 11054329 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 245
Study 8610901 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 2 mg
Number of subjects: 10
Study 8610901 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 1 mg
Number of subjects: 10
Study 8610901 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg and codeine 60 mg
Number of subjects: 10